Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.49 |
| ▸ | PTPN5 | P54829 | 3/20 | 0.49 |
| ▸ | DHODH | Q02127 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30914070 | 1.00 | ACSS2 (0.51) | ACSS2PTPN1PTPN5DHODHPOLB | |
| SCHEMBL13199189 | 0.88 | ACSS2 (0.51) | ACSS2POLBNPSR1MAPTMEN1 | |
| SCHEMBL1171941 | 0.86 | ACSS2 (0.48) | ACSS2PTPN5POLBNPSR1MAPT | |
| SCHEMBL1172441 | 0.86 | PIN1 (0.53) | ACSS2POLBNPSR1MAPTMEN1 | |
| SCHEMBL28846037 | 0.83 | PTPN5 (0.53) | PTPN1PTPN5RXRARXRB | |
| SCHEMBL2012390 | 0.83 | ACSS2 (0.48) | ACSS2PTPN5POLBNPSR1MAPT | |
| SCHEMBL30628323 | 0.83 | ACSS2 (0.48) | ACSS2PTPN5POLBNPSR1MAPT | |
| SCHEMBL31306494 | 0.83 | NPSR1 (0.50) | ACSS2POLBNPSR1MAPTMEN1 | |
| SCHEMBL17420423 | 0.82 | POLB (0.51) | ACSS2POLBNPSR1MAPTTHRB | |
| SCHEMBL17420520 | 0.82 | ACSS2 (0.47) | ACSS2POLBNPSR1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398757-A1 | INHIBITORS FOR CORONAVIRUSES | COCRYSTAL PHARMA, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4380920-A1 | INHIBITORS FOR CORONAVIRUSES | Cocrystal Pharma, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118103351-A | Coronavirus inhibitors | 共晶制药公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023014758-A1 | INHIBITORS FOR CORONAVIRUSES | COCRYSTAL PHARMA, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023014758-A1 | INHIBITORS FOR CORONAVIRUSES | COCRYSTAL PHARMA, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-9102622-B2 | Fatty acid amide hydrolase inhibitors | UNIVERSITY OF CONNECTICUT (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102622-B2 | Fatty acid amide hydrolase inhibitors | UNIVERSITY OF CONNECTICUT (US) | 2015-08-11 | — | — | US | disclosed |
| US-20110071178-A1 | Methods and Compounds for Modulating Cannabinoid Activity | NORTHEASTERN UNIVERSITY (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110039874-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2203058-A1 | METHODS AND COMPOUNDS FOR MODULATING CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2010-07-07 | — | — | EP | disclosed |
| EP-2203412-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20090306016-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | UNIVERSITY OF CONNECTICUT | 2009-12-10 | — | — | US | disclosed |
| EP-2051964-A2 | FATTY ACID AMIDE HYDROLASE INHIBITORS | University of Connecticut (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2009052320-A1 | METHODS AND COMPOUNDS FOR MODULATING CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052319-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2008013963-A2 | FATTY ACID AMIDE HYDROLASE INHIBITORS | UNIVERSITY OF CONNECTICUT (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398757-A1 | INHIBITORS FOR CORONAVIRUSES | ACE, ACE2, SARS1 | ACSS2 2501/4885PTPN1 2915/4885PTPN5 3297/4885 |
| US-20110039874-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | MGLL, FAAH, FAAH2 | ACSS2 612/4885PTPN1 2089/4885PTPN5 2096/4885 |
| US-20090306016-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | FAAH, FAAH2, CNR2 | ACSS2 181/4885PTPN1 4010/4885PTPN5 3876/4885 |
| US-20110071178-A1 | Methods and Compounds for Modulating Cannabinoid Activity | FAAH, FAAH2, CNR2 | ACSS2 825/4885PTPN1 2548/4885PTPN5 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.